Objectives:Pregnant women undergoing long-term organ transplant treatment have an increased incidence of delivering infants with intrauterine growth restriction (IUGR). Cyclosporine A is used as an immunosuppressant in such women and indirect evidence suggests that IUGR might result from an effect of cyclosporine A on amino acid transport by the placenta. In this study we tested the hypothesis that the transport of an essential amino acid, taurine, by fetal tissue other than the placenta is modulated by cyclosporine A.
Methods:Cord blood cells (CBCs) were used to test this hypothesis as an easily obtainable fetal tissue. Transport of taurine into CBCs was measured using standard tracer flux assays.
Results:Uptake of [3H] taurine by CBCs was linear over 15 minutes (76.2 ± 16.6 fmol/106 cells/min, mean ± SEM, n = 6) and inhibitable by 10 mM β-alanine, a substrate of the system-β taurine transport protein (6.7 ± 1.0 fmol/106 cells/min, n = 6, P < .05 paired Student t test). Pre-incubation with cyclosporine A (5 μM) inhibited [3H] taurine uptake by 29.3%-5.3% (n = 8, P < .05, paired Student t test).
Conclusions:These data show that amino acid transport via system-β can be measured in CBCs and may be a useful model for amino acid transport studies in fetal cells. We also show that system-β was inhibited by the immunosuppressant, cyclosporine A. This suggests that the increased incidence of IUGR reported in mothers treated with cyclosporine A may be due partially to effects on taurine uptake into fetal cells outside the placenta.
1. Pryor J. The identification and long term effects of fetal growth restriction. Br J Obstet Gynaecol1997;104:1116-1122.
2.
2. Fanaroff AA, Wright LL, Stevenson DK, et al. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, May 1991 through December 1992. Am J Obstet Gynecol1995;173:1423-1431.
3.
3. Blair E, Stanley F. Intrauterine growth and spastic cerebral palsy. I. Association with birth weight for gestational age. Am J Obstet Gynecol1990;162:229-237.
4.
4. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr2000;71:1344S-1352S.
5.
5. Leger J, Levy-Marchal C, Bloch J, et al. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: Regional cohort stury. Br Med J1997;315:341-347.
6.
6. Mahendran D, Donnai P, Glazier JD, et al. Amino acid (system A) transporter activity in microvillous membrane vesicles from the placentas of appropriate and small for gestational age babies. Pediatr Res1993;34:661-665.
7.
7. Jansson T, Scholtbach V, Powell TL. Placental transport of leucine and lysine is reduced in intrauterine growth restriction. Pediatr Res1998;44:532-537.
8.
8. Norberg S, Powell TL, Jnasson T. Intrauterine growth restriction is associated with a reduced activity of placental taurine transporters. Pediatr Res1998;44:233-238.
9.
9. Harrington B, Glazier J, D'Souza S, Sibley C. System A amino acid transporter activity in human placental microvillous membrane vesicles in relation to various anthropometric measurements in appropriate and small for gestational age babies. Pediatr Res1999;45:810-814.
10.
10. Huxtable RJ. Physiological actions of taurine. Physiol Rev1992;72:101-163.
11.
11. Sturman JA, Moretz RC, French JH, Wisniewski HM. Postnatal taurine deficiency in the kitten results in a persistence of the cerebellar external granule cell layer: Correction by taurine feeding. J Neurosci Res1985;13:521-528.
12.
12. Sturman JA, Messing JM. Dietary taurine content and feline reproduction and outcome. J Nutr1991;121:1195-1203.
13.
13. Sturman JA, Messing JM. High dietary taurine effects on feline tissue taurine concentrations and reproductive performance. J Nutr1992;122:82-88.
14.
14. Sturman JA. Taurine in development. Physiol Rev1993;73:119-147.
15.
15. Gaull G, Sturman JA, Raiha NC. Development of mammalian sulfur metabolism: absence of cystathionase in human fetal tissues. Pediatr Res1972;6:538-547.
16.
16. Ejiri K, Akahori S, Kudo K, Sekiba K, Ubuka T. Effect of guanidinoethyl sulfonate on taurine concentrations and fetal growth in pregnant rats. Biol Neonate1987;51:234-240.
17.
17. Ramamoorthy S, Leibach FH, Mahesh VB, et al. Functional characterization and chromosomal localization of a cloned taurine transporter from human placenta. Biochem J1994;300:893-900.
18.
18. Willis FR, Findlay CA, Gorrie MJ, et al. Children of renal transplant recipient mothers. J Paediatr Child Health2000;36:230-235.
19.
19. Pickrell MD, Sawers R, Michael J. Pregnancy after renal transplantation: Severe intrauterine growth retardation during treatment with cyclosporin A. Br Med J1988;296:825-825.
20.
20. Lamarque V, Leleu MF, Monka C, Krupp P. Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun. Transplant Proc1997;29:2480-2480.
21.
21. Cockburn IT, Krupp P, An appraisal of drug interactions with Sandimmun. Transplant Proc1989;21:3845-3850.
22.
22. Armenti VT, Stefanosky EV, Cater JR, et al. Pregnancy in transplant recipients. J Transpland Coord1995;5:130-136.
23.
23. Armenti VT, Moritz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression: Effects and outcomes. Drug Saf Con1998;19:219-232.
24.
24. Tendron A, Gouyon JB, Decramer S. In utero exposure to immunosuppressive drugs: Experimental and clinical studies. Pediatr Nephrol2002;17:121-130.
25.
25. Miniero R, Tardivo I, Curtoni ES, et al. Pregnancy after renal transplantation in Italian patients: Focus on fetal outcome. J Nephrol2002;15:626-632.
26.
26. Mason RJ, Thomson AW, Whiting PH, et al. Cyclosporine-induced fetotoxicity in the rat. Transplantation1985;39:9-12.
27.
27. Pavek P, Fendrich Z, Staud F, et al. Influence of P-glycoprotein on the transplacental passage of cyclosporine. J Pharm Sci2001;90:1583-1592.
28.
28. Ramamoorthy S, Leibach FH, Mahesh VB, Ganapathy V. Selective impairment of taurine transport by cyclosporin A in a human placental cell line. Pediatr Res1992;32:125-127.
29.
29. Wan TS, Tam AY, Yeung CY. Neutrophil separation technique for neonates. Br J Biomed Sci1999;56:205-208.
30.
30. Furesz TC, Moe AJ, Smith CH. Two cationic amino-acid-transport systems in human placental basal plasma-membranes. Am J Physiol1991;261:C246-C252.
31.
31. Karl PI, Fisher SE. Taurine transport by microvillous membrane vesicles and the perfused cotyledon of the human placenta. Am J Physiol1990;258:C443-C451.
32.
32. Segel GB. Haematology of the newborn. In: Williams WJ, ed. William's Haematology. London: McGraw-Hill, 1995:57-62.
33.
33. Kanemori H, Ejiri K, Akahori S, Kudo T, Sekiba K, Concentration and uptake of taurine in umbilical blood platelets. Acta Med Okayama1992;46:169-174.
34.
34. Motais R, Fievet B, Borgese F, Garcia-Romeu F. Association of the band 3 protein with a volume-activated, anion and amino acid channel: A molecular approach. J Exp Biol1997;200:361-367.
35.
35. Gonska T, Hirsch JR, Schlatter E. Amino acid transport in the renal proximal tubule. Amino Acids2000;19:395-407.
36.
36. Chesney RW, Jax DK. Development aspects of renal beta-amino acid transport II. Ontogeny of uptake and efflux processes and effect of anoxia. Pediatr Res1979;13:861-867.
37.
37. Moyer MS, Goodrich AL, Rolfes MM, Suchy FJ. Ontogenesis of intestinal taurine transport: Evidence for a beta-carrier in developing rat jejunum. Am J Physiol1988;254:G870-G877.
38.
38. Kim HW, Lee EJ, Kim WB, Kim BK. Ionomycin restores taurine transporter activity in cyclosporin-A treated macrophages. Adv Exp Med Biol2000;483:127-135.
39.
39. Shaw KT, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA1995;92:11205-11209.
40.
40. Lima L, Cubillos S, Guerra A. Regulation of high affinity taurine transport in goldfish and rat retinal cells. Adv Exp Med Biol2000;483:431-440.
41.
41. Padma S, Subramanyam C. Extracellular calcineurin: Identification and quantitation in serum and amniotic fluid. Clin Biochem1999;32:491-494.
42.
42. Venkataramanan R, Koneru B, Wang C, et al. Cyclosporine and its metabolites in mother and baby. Transplantation1988;46:468-469.
43.
43. Scantlebury V, Gordon R, Tzakis A, et al. Childbearing after liver transplantation. Transplantation1990;49:317-321.
44.
44. Tegzess AM, Doorenbos BM, Minderhoud JM, Donker AJ. Prospective serial renal function studies in patients with non-renal disease treated with cyclosporine A. Transplant Proc1988;20:390-393.
45.
45. Bertin E, Gangnerau M, Bellon G, et al. Development of beta-cell mass in fetuses of rats deprived of protein and/or energy in last trimester of pregnancy. Am J Physiol2002;283:R623-R630.
46.
46. Nag TC, Jotwani G, Wadhwa S. Immunohistochemical localization of taurine in the retina of developing and adult human and adult monkey. Neurochem Int1998;33:195-200.
47.
47. Heller-Stilb B, van Roeyen C, Rascher K, et al. Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J2002;16:231-233.
48.
48. Aerts L, Van Assche FA. Taurine and taurine-deficiency in the perinatal period. J Perinat Med2002;30:281-286.
49.
49. Han X, Budreau AM, Chesney RW. The taurine transporter gene and its role in renal development. Amino Acids2000;19:499-507.
50.
50. Jansson T. Amino acid transporters in the human placenta. Pediatr Res2001;49:141-147.
